Bulletin from Annual General Meeting in Karessa Pharma Holding AB (publ) on the 29th of May 2017
At Karessa Pharma Holding AB (publ)'s Annual General Meeting on May 29th 2017, all members of the Board of Directors and the Chairman of the Board were re-elected. The Annual General Meeting approved a directed issue of stock options.
The Annual General Meeting decided that the result of the year, SEK 0, shall be carried forward.
The Annual General Meeting approved to re-elect all members of the Board; Ulf Lindberg, Scott Boyer, Stefan Arver and Michael Brobjer. Ulf Lindberg was re-elect as the Chairman of the Board. Moreover, the Annual General Meeting approved payment of remuneration to the Board of Directors of SEK 250,000 to the Chairman and SEK 100,000 to the other board members, except for the CEO. Thus a total amount of SEK 450,000. Fees to the auditors were approved as specified in the approved invoice.
The Annual General Meeting also decided to re-elect the auditor with authorised accountant Hans Brorsson and also the registered accounting company Crowe Horwath Osborne AB, corporate identity number 556068-8813, with authorised accountant Olov Strömberg as lead auditor, was elected as a new auditor alongside Hans Brorsson until the next Annual General Meeting.
The Annual General Meeting also decided to issue a maximum of 330,000 stock options. Each stock option shall entitle the holder to subscribe a new share for SEK 20 at the latest on 29thof May 2020. With the exception of shareholders' preferential rights, the subscriber shall be a wholly-owned subsidiary of Karessa Pharma Holding AB for the transfer to current and future leading executives in the Group. The transfer shall be at a price corresponding to the market value determined in accordance with the Black & Scholes valuation model for stock options. If the 450,000 stock options issued by the Annual General Meeting 2015 are fully utilized, the proposed issue will result in a dilution of approximately 2.8% of the votes and capital of the company.
This information is such information that Karessa Pharma Holding AB (publ) is obliged to disclose public according to the European Union's Market Abuse Regulation. The information was provided by the contact person below for publication on 29 May 2017, 17.00 CET.
FOR MORE INFORMATION, PLEASE CONTACT:
Michael Brobjer, CEO, Karessa Pharma Holding AB (publ)
Tel: +46 8-768 22 33
Email: michael.brobjer@karessa.se
About Karessa Pharma Holding AB
Karessa develops new pharmaceuticals based on a patented drug delivery technology and proven pharmaceutical substances in order to offer men with impotence problems a fast and more reliable effect. Karessa is listed on Nasdaq First North and has Remium as Certified Advisor. For more information, please visit karessa.se
Tags: